Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02963727

Enrollment

Registered

2016-11-15

Start date

2017-01-27

Completion date

2021-12-31

Last updated

2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthrosis

Keywords

osteoarthrosis, Knee, Wharton Jelly

Brief summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Detailed description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Interventions

BIOLOGICALWharton Jelly derived mesenchymal stem cell

Intra-articular Wharton Jelly derived mesenchymal stem cell injection.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

42 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Severe KOA stage III or IV by Laurance & Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint. * Willing to participate by signing the informed consent

Exclusion criteria

1. Sublaxation beyond 20 degrees of the bones of the knee joint 2. Oral anticoagulants or heparin therapy 3. Heart failure or arrhythmia 4. Body Mass Index \> 35 5. Uncontrolled Diabetes Mellitus. 6. Evidence of Infectious Diseases. 7. Active infection 8. Malignancy 9. Pregnancy 10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000. 11. Unreliable patients 12. Non-resident in Jordan

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the safety and tolerability of the intra articular injection	6 months	patients will be monitored for any adverse events resulting from the intraarticular injection of WJMSC

Secondary

Measure	Time frame	Description
Assessment of the efficacy of intra-articular injection of WJMSC	12 months	The efficacy of the intra-articular injection of WJMSC will be assessed by Magnetic Resonance Imaging (MRI).

Countries

Jordan

Contacts

Primary ContactHanan Jafar, PhD

hanan.jafar@gmail.com00962798871087

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026